While artificial intelligence (AI) technology sweeps across the globe, reshaping industries from finance to telecommunications and giving rise to market stars, investor attention is often captivated by this seemingly unstoppable technological wave. However, there are domains that AI struggles to reach, both now and likely in the future—such as curing diseases. In this dimension, biotechnology companies are demonstrating investment return potential comparable to leading AI players, leveraging their capacity to develop breakthrough therapies. Among them, gene-editing specialist CRISPR Therapeutics (CRSP) stands out as a compelling option.
The core strength of CRISPR Therapeutics lies in its gene-editing platform, which focuses on developing transformative therapies for disease areas that currently lack effective treatments or urgently need new solutions. Several candidate products in its pipeline illustrate this strategic direction.
For Type 1 diabetes, the candidate therapy CTX211 aims to restore patients’ own insulin production, offering potential curative hope for patients who typically rely on external insulin for survival. In the anticoagulation field, the candidate product SRSD107 strives to overcome the limitations of existing drugs, which may cause severe bleeding or require daily dosing, by developing a long-acting option with fewer side effects. Additionally, CTX310 targets the reduction of low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol) and triglycerides (TGs). Elevated levels of these can trigger a series of cardiovascular issues, potentially leading to serious illness or even death. Considering that commonly used lipid-lowering drugs often require daily intake, CTX310, potentially a one-time treatment, holds significant promise in a market of approximately 40 million relevant patients.
The value of the company’s gene-editing platform has received initial validation: its developed therapy, Casgevy, has gained regulatory approval for treating two rare blood disorders.
At a time when some investors worry about a potential bubble in the AI sector, CRISPR Therapeutics, as a non-AI, small-to-mid-sized biotech company with high growth potential, offers a differentiated investment choice. However, investing in it comes with inherent risks: setbacks in clinical trials or regulatory approvals could severely impact its stock price. Simultaneously, gene-editing drugs, being relatively novel and expensive therapies, still face challenges in gaining widespread acceptance from third-party payers. Investors need to fully consider these risk factors before making decisions. Yet, for investors with a higher risk tolerance, its long-term potential may be quite attractive.
CRISPR Therapeutics has been included in Cathie Wood’s curated “Growth Stock Portfolio: 12 Stock Picks” list. Recently, Bank of America analyst Alec Stranahan adjusted CRISPR Therapeutics’ price target slightly from $90 to $89 but maintained a “Buy” rating. The adjustment primarily stemmed from a slight downward revision of the revenue forecast for Casgevy in 2026. However, Bank of America still expects the product to show continuous improvement momentum leading up to 2026.
With its expertise in gene editing and an innovative pipeline targeting significant unmet medical needs, CRISPR Therapeutics carves out a unique life sciences investment path distinct from the AI-dominated tech investment frenzy. Although investing in biotech companies requires facing risks related to clinical development, regulation, and market access, for investors seeking portfolio diversification, focusing on fundamental human health challenges, and possessing corresponding risk tolerance, the cutting-edge biotechnological innovation represented by this company warrants close attention. When assessing its long-term value, the company’s scientific execution, pipeline advancement progress, and the commercial success of key products will be more important metrics than short-term stock price fluctuations.
